IVA - Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea
2023-09-21 01:42:37 ET
More on Inventiva
- Seeking Alpha’s Quant Rating on Inventiva
- Historical earnings data for Inventiva
- Financial information for Inventiva
- Inventiva: An Untenable Cash Position Despite Enviable Data
- Inventiva announced €35.7M funding, eyes future raise to meet obligations
For further details see:
Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea